TrialPLoS medicine2022

Safety and immunogenicity of heterologous boost immunization with an adenovirus type-5-vectored and protein-subunit-based COVID-19 vaccine (Convidecia/ZF2001): A randomized, observer-blinded, placebo-controlled trial.

Pengfei Jin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.